April - 2014
| Previous Next | Showing Journal 10 of 15 |
Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolismthe PEITHO Investigators NEJM, 2014, 370:1402-1411 This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
April |
Previous Comments
| For crying out aloud will someone please follow up the respiratory function and health related quality of life on these patients. Of course mortality was no different, it's too rare. | |
| Motown Philippe-13 Apr, 2014 11:49:55 AM | |
| Amen Motown. | |
| LTC-16 Apr, 2014 09:50:11 AM | |
| It never got much attention... but the MOPETT trial in 2012 showed an 40%ARR in pulmonary hypertension at 6 months (15% in thrombolysis and 50% in anticoagulation alone). They also looked at functional status and those thrombolysed had much better function. I'm not sure why it never received attention from the critical care world - published in the american journal of cardiology? only had half dose thrombolysis? high prevalence of pulmonary hypertension at 6 months? Anyway - I thought is was well worth repeating as in terms of symptom control at 6 months it definitely go my attention. | |
| Cynthia-16 Jul, 2014 05:38:09 PM | |
Comment
The decision about whether or not to thrombolyse the “intermediate-risk” PE remains difficult. In the past 40 years there have been fewer than 1000 patients enrolled in RCTs of heparin vs lysis for PE?
This multi-center prospective RCT tries...